April 10, 2026 a 05:00 pm
ABBV: Analysts Ratings - AbbVie Inc.
AbbVie Inc. has seen a stable performance in its stock ratings. The dominant "Buy" recommendations suggest positive growth prospects, while the presence of "Hold" ratings reflects a measured market sentiment. The absence of "Sell" ratings demonstrates confidence in AbbVie's current trajectory.
Historical Stock Grades
| Recommendation | Number | Score |
|---|---|---|
| Strong Buy | 8 | |
| Buy | 14 | |
| Hold | 9 | |
| Sell | 0 | |
| Strong Sell | 0 |
Sentiment Development
Over the last few months, AbbVie has maintained a consistent analyst rating profile with a solid number of "Buy" recommendations and very few shifts toward negative sentiment. Notable trends include:
- Steady increase in "Strong Buy" recommendations earlier in 2026.
- Consistent number of "Hold" ratings suggests cautious optimism.
- No "Sell" or "Strong Sell" ratings warranting a negative outlook.
Percentage Trends
Analysts have shown stability in their recommendations with some fluctuations in the composition of ratings over the past 12 months:
- April 2026 saw 44% "Strong Buy" and 78% "Buy", indicating strong continued interest in purchasing the stock.
- The percentage of "Hold" ratings remains close to 50%, reflecting a balanced market sentiment.
- The decrease in "Strong Buy" ratings from the past year is offset by stable "Buy" and consistent "Hold" levels.
Latest Analyst Recommendations
Recent analyses maintain a largely positive outlook for AbbVie, as the following table of the latest recommendations shows:
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2026-04-08 | Overweight | Overweight | Cantor Fitzgerald |
| 2026-02-18 | Overweight | Overweight | Piper Sandler |
| 2026-02-17 | Buy | Buy | Freedom Broker |
| 2026-02-05 | Neutral | Neutral | UBS |
| 2026-02-05 | Outperform | Outperform | Evercore ISI Group |
Analyst Recommendations with Change of Opinion
Although most analysts have maintained their prior ratings, there have been some opinion changes that indicate recent sentiment shifts:
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2026-01-08 | Peer Perform | Outperform | Wolfe Research |
| 2025-12-10 | Buy | Hold | HSBC |
| 2025-10-01 | Hold | Buy | HSBC |
| 2025-09-17 | Buy | Hold | Berenberg |
| 2025-05-14 | Neutral | Buy | Citigroup |
Interpretation
The market sentiment surrounding AbbVie Inc. remains predominantly positive, indicated by a higher frequency of "Buy" and "Strong Buy" recommendations. Despite some downgrades to "Hold" or "Neutral," the absence of negative forecasts suggests confidence in the company's strategic direction and future profitability. This balance between optimism and caution reflects a stable analyst sentiment.
Conclusion
The continuous prevailing of "Strong Buy" and "Buy" signals positions AbbVie as a favored stock among investors, indicating positive long-term prospects. The consistent "Hold" ratings reflect a cautious approach that investors typically adopt in uncertain market conditions. Nonetheless, the overarching absence of "Sell" recommendations enhances confidence in maintaining or expanding investments in AbbVie Inc., suggesting minimal perceived risk for the near future.